November 1, 2009
By: Jill Wechsler
FDA reviewers strive to assess new postmarketing programs while also evaluating applications.
 |
November 1, 2009
By:Peter O'Donnell
Health concerns require EU regulators to become more involved in the politics of health care.
|
November 1, 2009
How Italy's new quality-driven regulations will ask more of CROs conducting activities in the country.
|
November 1, 2009
By:Josip Aralica
As a part of Europe, but not the European Union, trials in Croatia can encounter special challenges
|
October 22, 2009
By:Marissa Shapiro
Why knowing a drug's risk and preparing for a risk evaluation mitigation strategy early on will considerably benefit a drug's development.
|
October 1, 2009
By:Peter O'Donnell
The EU struggles to get over its regulatory hurdles in an effort to further R&D success.
|
October 1, 2009
By:Jill Wechsler
Stiffer enforcement of research standards aims to restore the public's confidence in agency actions.
|
October 1, 2009
By:Juliane Carvalho, Ekopimo Ibia
The region and its regulatory agencies try to keep up with the rapidly growing clinical trials market.
|
September 1, 2009
By:Jill Wechsler
International health crises expand testing of new vaccines and drug treatments for third-world diseases.
|
| 
